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Abstract
Background: Newborn screening (NBS) for CF has become widespread, although there are multiple strategies. Little is known about outcomes
such as age of diagnosis after different NBS methods.
Methods: We used the U.S. Cystic Fibrosis Foundation Patient Registry to identify infants with CF born between 2001 and 2008 in states that
utilized NBS. We compared ages at diagnosis, genotyping, sweat test, and ﬁrst visit to a CF Centre between states that used serial immunoreactive
trypsinogen (IRT/IRT) levels and states that used IRT and DNA analysis (IRT/DNA).
Results:We identiﬁed 1288 infants with CF. Compared to infants born in IRT/IRT states, infants born in IRT/DNA states were younger at the time
of diagnosis (median 2.3 weeks versus 4.0 weeks in IRT/IRT states, pb0.001), genotyping (0.7 weeks versus 5.3 weeks, pb0.001), and initial CF
Centre visit (5.9 weeks versus 7.7 weeks, p=0.008).
Conclusions: Although there is room to improve outcomes with both strategies, infants born in IRT/DNA states have treatment initiated at a younger
age than infants born in IRT/IRT states.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Newborn screening (NBS) is used to facilitate presympto-
matic diagnosis and has been applied to cystic fibrosis (CF)
since the early 1980s in Europe, Australia and New Zealand,
and the U.S. [1,2]. The initial algorithm [2] demonstrating
elevated values of immunoreactive trypsinogen on two blood
specimens (IRT/IRT) is still used widely today. The U.S. CF
Foundation recommends that the two blood specimens be
obtained around day 2 and day 14 of life [3]. Because of concerns
[4] regarding suboptimal sensitivity of IRT/IRT, and the ability
to test for CF transmembrane conductance regulator (CFTR)
gene mutations [5], combining IRT with DNA analysis (IRT/☆ Data from this manuscript was presented at the North American Cystic
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⁎ Corresponding author at: American Family Children's Hospital, 600 Highland
Avenue, K4/920,Madison,WI 53792-9988, United States. Tel.: +1 608 265 3425;
fax: +1 608 263 0510.
E-mail address: dbsanders@pediatrics.wisc.edu (D.B. Sanders).
1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2011.10.002DNA)for CFTR mutations on a single blood specimen was de-
veloped and is now used in many European countries and U.S.
states [6–8]. However, utilizing DNA analysis has several
potential disadvantages that may be avoided using IRT/IRT:
DNA analysis may increase the recognition of carriers, children
with an equivocal diagnosis, and children with misidentified
paternity [9].
Studies of the benefits of NBS have revealed improvements
in nutrition that are most apparent for those treated in the first
two months of life [10,11], and there is evidence of poor nutri-
tion as early as 2 weeks of age in some infants with CF [12–
14]. More recently, analysis of the CF NBS programs in France
in 2002–2005 revealed that, excluding infants with meconium
ileus, 52% of the infants were symptomatic at the initial CF
Centre visit, which occurred at a median age of 34 days [15].
Because of the importance of prompt identification and
treatment of infants with CF, and reports of possible delays
using IRT/IRT methodology [2,4,16], we hypothesized that
infants born in regions that use IRT/DNA would be diagnosedby Elsevier B.V. All rights reserved.
Table 1
Comparison of infants born in IRT/DNA and IRT/IRT states in 2001–2008.
Median (25th, 75th percentiles) age in
weeks
IRT/DNA (N=968) IRT/IRT (N=320) p-value
Diagnosis age 2.3 (0.3, 5.1) 4.0 (2.7, 7.4) b0.001
Sweat test age ⁎ 4.4 (2.7, 9.3) 4.3 (3.0, 8.3) 0.65
Genotype age ⁎⁎ 0.7 (0.1, 4.4) 5.3 (3.4, 10.1) b0.001
First CF Centre visit age 5.9 (3.0, 15.1) 7.7 (4.0, 13.9) 0.008
⁎ Sweat tests were not reported for 136 (14%) in IRT/DNA states and 86
(27%) in IRT/IRT states, pb0.001.
⁎⁎ Genotype was not reported for 40 (4%) in IRT/DNA states and 38 (12%) in
IRT/IRT states, pb0.001.
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nosed after IRT/IRT screening. Additionally, our experience
with NBS in Wisconsin led us to perform several quality im-
provement (QI) initiatives to improve our NBS program [17].
To assess the effectiveness of these QI projects, we compared
our data to other states' data using the U.S. Cystic Fibrosis
Foundation Patient Registry (CFFPR). Our aim was to deter-
mine if infants with CF were diagnosed and treated earlier in
states that used IRT/DNA, and whether QI initiatives imple-
mented in Wisconsin led to improvements. Some of the results
of these studies have been previously reported in the form of an
abstract [18].
2. Methods
Data from the CFFPR [19–21] from 2001 to 2008 was used
to identify infants with CF born in states that had implemented
NBS before 31/12/2008. The first year of NBS implementation
was excluded from this analysis. Infants diagnosed through
prenatal screening or with meconium ileus were excluded.
Because data was not normally distributed, we used the me-
dian score test to compare ages at relevant dates for children
with CF diagnosed in IRT/DNA and IRT/IRT states. To eval-
uate trends over time, we compared relevant dates between
2001 and 2004 and 2005–2008. We repeated comparisons,
using only infants with CF with an abnormal NBS result, as
entered in the CFFPR. Results were compared against CF
Foundation recommendations [6]. Finally, we compared the
age at relevant dates between children born in Wisconsin to
other states to evaluate the effect of QI efforts [17].
3. Results
There were 1611 infants from 23 IRT/DNA and 13 IRT/IRT
states that used NBS for at least one year during 2001–2008Patients born with CF in
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Fig. 2. Age at diagnosis (A) and initial CF Centre visit (B). IRT/DNA in gray,
IRT/IRT in white.
Table 2
Quality improvement procedures undertaken in Wisconsin to improve CF newborn
screening.
The IRT assay was changed from a radiometric to a fluorescent dissociation
enhanced lanthanide fluorescence immunoassay method.
A “floating” IRT referral level for DNA testing was introduced to minimize
seasonal effects on measured IRT levels.
The IRT referral level for DNA testing was decreased from the 98.5th to the
94th percentile; this was later revised up to the 96th percentile to minimize
carrier detection.
DNA testing was performed 3 days per week (increased from 1 day per week
previously).
DNA detection changed from F508del only to routine screening for the
American College of Medical Genetics (ACMG) 25 CF transmembrane
conductance regulator (CFTR) mutations using a strip detection system
(CF-Gold LAp, Roche Molecular Biochemicals) in March, 2002. When
R117H is detected, reflex testing for the polythymidine tract in intron
8 (5T, 7T, and 9T) is performed. In July 2008, the screening changed to
the ACMG 23 CFTR mutations using the Invader® Assay (Hologic Inc.).
Infants with IRT levels higher than the 99.9th percentile but without detectable
CFTR mutations are reported as “possible” abnormal. Sweat testing is
recommended when there are symptoms or a positive family history.
As a quality control measure, the Wisconsin State Newborn Screening lab
routinely analyzes specimens with abnormal results in a blinded fashion to
ensure repeatability of results.
The Wisconsin State Newborn Screening lab implemented a formal process to
follow up on all abnormal results to maximize the likelihood that a follow
up sweat test would be performed.
Primary care providers are notified by phone by the Wisconsin State Newborn
Screening lab when two disease-causing mutations are identified.
Sweat tests are scheduled as soon as possible, as long as the infant weighs at
least 2.95 kilograms.
In 2005, sweat tests were made available at an affiliate CF Centre to decrease
the distance some patients had to travel.
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4.3 weeks in IRT/IRT states, pb0.001.
4. Discussion
We found that infants born in states that utilized IRT/DNA
methodology were diagnosed, genotyped, and seen for an ini-
tial CF Centre visit at younger ages than infants born in states
that utilized IRT/IRT methodology. Similar results were
reported in a survey of CF NBS programs in Europe that used
more heterogeneous NBS strategies [22]. Nineteen of the 26
NBS programs in Europe used DNA analysis as part of their
NBS; these 19 programs reported a significantly younger medi-
an age at diagnosis (approximately 5 weeks, compared to ap-
proximately 8 weeks for programs that did not use DNA in their
NBS programs), although there is no data on age of sweat
test or first CF Centre visit [22]. It is apparent that the IRT/
IRT protocol leads to a longer time to diagnosis, although
IRT/DNA protocols are likely to increase the recognition of
carriers, children with an equivocal diagnosis, and children
with misidentified paternity [9].
The U.S. CF Foundation has recommended that a sweat test
be performed following a positive NBS by 2–4 weeks of age,including results with 2 mutations detected by DNA analysis
[6]. At the time of a positive sweat test, a CF clinician should
evaluate the patient, develop short-term treatment plans with the
parents, and schedule an initial CF Centre visit by 1–2 months
of age [3,6]. The European CF Society recommends that a
sweat test preferably be performed in the first month of life
[24]. These goals were formulated with the intention of maximiz-
ing potential benefits to patients with CF. Our findings indicate
that these goals were not being met for a large proportion of
infants: at least half of patients in our study were sweat tested
after the first month of life. The median age at the first CF Centre
visit did fall within the recommended range for both IRT/DNA
and IRT/IRT states, but 37% of infants with CF in IRT/DNA
and 40% in IRT/IRT states were not seen for their initial visit
until after 8 weeks of age.
While all NBS programs have the potential for delayed care,
or even missed cases, QI can minimize negative outcomes and
maximize positive ones. After our experience with theWisconsin
Randomized Control Trial of CF Newborn Screening, the
Wisconsin NBS program made several changes [17] designed
to increase the efficiency of the screening process and mini-
mize the time to sweat testing (Table 2). After making those
changes, we report in the current study that infants in Wisconsin
were younger at their sweat test and first CF Centre visit than
infants born in other IRT/DNA or IRT/IRT states.
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has been used in many studies of patients with CF [19–21],
data entry on diagnosis-related variables is not standardized.
This is demonstrated by the distribution of diagnosis dates,
where the diagnosis date is listed as the birth date for 11% of
infants born in IRT/IRT states and 14% of infants born in
IRT/DNA states. While this limits our ability to interpret differ-
ences in the diagnosis date, we expect that the sweat test and
initial CF Centre visit dates are reliable, as these dates are clearly
recorded in the patients' medical records. Additionally, a sur-
prisingly high number of infants were reported to not have
had a positive newborn screening result (18–28%). This is
most likely due to this box not being checked during entry of
data into the CFFPR, since our results were similar when we
restricted our analysis to infants with a positive newborn
screening result. Second, while we excluded the first year of
data in states that began CF NBS programs during 2001–2008,
one year may not be sufficient for NBS programs to establish
best practices. Third, we do not have any information on false
positive NBS results and potential negative outcomes (e.g.,
carrier recognition, equivocal diagnosis, or misidentified pa-
ternity). Finally, we can only speculate on the possible reasons
for delayed dates of diagnosis and initial CF Centre visits in
IRT/IRT states, although it is known that the IRT/IRT method
has a higher rate of false negative tests [2], is more difficult to
apply to premature infants [23], depends on the timing of blood
sampling [16], and requires successful procurement of a
second specimen (which fails in 5–20% [2]). The longer delays
we discovered with the IRT/IRT method probably apply as
well to the IRT/IRT/DNA algorithm used in a few states. It is
not surprising that genotyping occurs earlier in IRT/DNA
states, since DNA analysis is integral to the protocol.
In conclusion, during the years 2001–2008, IRT/DNA states
diagnosed and treated infants with CF at younger ages than
IRT/IRT states. In both IRT/DNA and IRT/IRT states, there
is need for quality improvements that can shorten the time to di-
agnosis and treatment. Additionally, there is need for quality
improvements in data entry into CF registries if the CF community
is to use these valuable resources to continue to improve our
newborn screening processes.
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